WO1989006692A1
(en)
*
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
US6884418B1
(en)
|
1989-08-04 |
2005-04-26 |
Berlex Laboratories, Inc. |
Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
|
WO1992007466A1
(en)
*
|
1990-11-05 |
1992-05-14 |
Bristol-Myers Squibb Company |
Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6417168B1
(en)
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
PL348634A1
(en)
|
1998-05-15 |
2002-06-03 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
|
US20080096236A1
(en)
*
|
1998-08-25 |
2008-04-24 |
Binax, Inc. |
Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof
|
US6824997B1
(en)
*
|
1998-09-18 |
2004-11-30 |
Binax, Inc. |
Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
|
US9134303B1
(en)
|
1998-08-25 |
2015-09-15 |
Alere Scarborough, Inc. |
ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
|
RU2294761C2
(ru)
*
|
1999-05-14 |
2007-03-10 |
Имклон Систимс Инкопэритид |
Лечение резистентных опухолей человека антагонистами рецепторов фактора роста эпидермиса
|
TWI269654B
(en)
|
1999-09-28 |
2007-01-01 |
Baxter Healthcare Sa |
N-substituted indole-3-glyoxylamide compounds having anti-tumor action
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
CA2409991A1
(en)
*
|
2000-05-24 |
2001-11-29 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
EP1170011A1
(de)
*
|
2000-07-06 |
2002-01-09 |
Boehringer Ingelheim International GmbH |
Neue Verwendung von Inhibitoren der Rezeptoren des epidermalen Wachstumsfaktors
|
CA2418083A1
(en)
*
|
2000-08-09 |
2002-02-14 |
Imclone Systems Incorporated |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
MX242553B
(es)
*
|
2000-10-20 |
2006-12-06 |
Eisai Co Ltd |
Derivados aromaticos que contienen nitrogeno.
|
US7906492B2
(en)
*
|
2001-01-16 |
2011-03-15 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
US7507724B2
(en)
|
2001-01-16 |
2009-03-24 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
MXPA03009683A
(es)
|
2001-04-24 |
2004-02-12 |
Merck Patent Gmbh |
TERAPIA EN COMBINACIoN USANDO AGENTES ANTIANGIOGENICOS Y FACTOR DE NECROSIS TUMORAL ALFA.
|
DK2163256T3
(en)
*
|
2001-05-11 |
2015-12-07 |
Ludwig Inst For Cancer Res Ltd |
Specific binding proteins and use thereof
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
IL159225A0
(en)
|
2001-06-13 |
2004-06-01 |
Genmab As |
Human monoclonal antibodies to epidermal growth factor receptor (egfr)
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
CA2452058A1
(en)
*
|
2001-06-26 |
2003-01-09 |
Imclone Systems Incorporated |
Bispecific antibodies that bind to vegf receptors
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
JP4303105B2
(ja)
*
|
2001-06-28 |
2009-07-29 |
ドマンティス リミテッド |
二重特異性リガンドとその利用
|
DE10133394A1
(de)
*
|
2001-07-13 |
2003-01-30 |
Merck Patent Gmbh |
Flüssige Formulierung enthaltend Cetuximab
|
EP2298346A3
(de)
|
2002-03-04 |
2011-11-16 |
Imclone LLC |
KDR-spezifische menschliche Antikörper und ihre Verwendung
|
AU2003211594A1
(en)
*
|
2002-03-05 |
2003-09-16 |
Eisai Co., Ltd. |
Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
|
NZ571508A
(en)
*
|
2002-05-24 |
2010-05-28 |
Schering Corp |
Neutralizing human anti-IGFR antibody
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
SI1517921T1
(sl)
*
|
2002-06-28 |
2006-10-31 |
Domantis Ltd |
Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo
|
PL374586A1
(en)
*
|
2002-10-10 |
2005-10-31 |
Merck Patent Gmbh |
Bispecific anti-erb-b antibodies and their use in tumor therapy
|
US20040147428A1
(en)
*
|
2002-11-15 |
2004-07-29 |
Pluenneke John D. |
Methods of treatment using an inhibitor of epidermal growth factor receptor
|
TWI229650B
(en)
*
|
2002-11-19 |
2005-03-21 |
Sharp Kk |
Substrate accommodating tray
|
AU2003290330A1
(en)
*
|
2002-12-27 |
2004-07-22 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
ATE508747T1
(de)
|
2003-03-10 |
2011-05-15 |
Eisai R&D Man Co Ltd |
C-kit kinase-hemmer
|
EP1622941A2
(de)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Methode zur produktion von anti-egfr antikörpern
|
US7425328B2
(en)
*
|
2003-04-22 |
2008-09-16 |
Purdue Pharma L.P. |
Tissue factor antibodies and uses thereof
|
US7638605B2
(en)
|
2003-05-01 |
2009-12-29 |
ImClone, LLC |
Fully human antibodies directed against the human insulin-like growth factor-1 receptor
|
WO2005001053A2
(en)
|
2003-06-09 |
2005-01-06 |
Samuel Waksal |
Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
|
US7628986B2
(en)
|
2003-06-27 |
2009-12-08 |
Amgen Fremont Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
PT1687338E
(pt)
|
2003-11-07 |
2011-01-20 |
Ablynx Nv |
Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
|
JP4303726B2
(ja)
*
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウレア誘導体およびその製造方法
|
PE20050928A1
(es)
*
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
DE10355904A1
(de)
*
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
US7767792B2
(en)
*
|
2004-02-20 |
2010-08-03 |
Ludwig Institute For Cancer Research Ltd. |
Antibodies to EGF receptor epitope peptides
|
DK1735348T3
(da)
|
2004-03-19 |
2012-07-16 |
Imclone Llc |
Humant anti-epidermalt vækstfaktorreceptorantistof
|
TWI351284B
(en)
|
2004-04-09 |
2011-11-01 |
Chugai Pharmaceutical Co Ltd |
Novel water-soluble prodrugs
|
NZ582684A
(en)
*
|
2004-06-18 |
2011-05-27 |
Ambrx Inc |
Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker
|
US8772269B2
(en)
*
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
CN101001629B
(zh)
|
2004-09-17 |
2010-05-05 |
卫材R&D管理有限公司 |
药物组合物
|
WO2006042313A2
(en)
*
|
2004-10-12 |
2006-04-20 |
Imclone Systems Incorporated |
Egfr antagonist in treatment of fluid accumulation
|
JP2008519757A
(ja)
*
|
2004-11-12 |
2008-06-12 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
抗egfr抗体の固形物
|
WO2006090930A1
(ja)
*
|
2005-02-28 |
2006-08-31 |
Eisai R & D Management Co., Ltd. |
スルホンアミド化合物の新規併用
|
AU2006236637B2
(en)
*
|
2005-04-15 |
2012-09-06 |
Merck Sharp & Dohme Corp. |
Methods and compositions for treating or preventing cancer
|
US20090214562A1
(en)
*
|
2005-05-03 |
2009-08-27 |
Karel Steven J |
Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
|
NZ564098A
(en)
|
2005-06-15 |
2010-04-30 |
Schering Corp |
Anti-IGF1R antibody formulations
|
EP2100618B1
(de)
|
2005-06-17 |
2014-02-12 |
ImClone LLC |
Ein anti-PDGFR-alpha Antikörper zur Behandlung von metastasierendem Knochenkarzinom
|
JP2007039346A
(ja)
*
|
2005-08-01 |
2007-02-15 |
Yokohama Kokusai Bio Kenkyusho:Kk |
腫瘍特異的抗体と結合したタキソイド誘導体及びその製造方法
|
EP1925941B1
(de)
*
|
2005-08-01 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Verfahren zur vorhersage der wirksamkeit eines vaskularisierungsinhibitors
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
TW200744603A
(en)
|
2005-08-22 |
2007-12-16 |
Chugai Pharmaceutical Co Ltd |
Novel anticancer concomitant drug
|
WO2007026864A1
(ja)
*
|
2005-09-01 |
2007-03-08 |
Eisai R & D Management Co., Ltd. |
崩壊性の改善された医薬組成物の製造方法
|
BRPI0617236A2
(pt)
|
2005-10-11 |
2011-07-19 |
Merck Patent Gmbh |
modulação da expressão de quimiocina, dependente de egfr, e influência sobre a terapia e diagnóstico de tumores e efeitos colaterais da mesma
|
EP1949902B1
(de)
*
|
2005-11-07 |
2012-06-27 |
Eisai R&D Management Co., Ltd. |
Verwendung einer kombination einer anti-angiogenen substanz und c-kit-kinase-hemmer
|
EP3173084B1
(de)
|
2005-11-11 |
2019-10-23 |
Boehringer Ingelheim International GmbH |
Chinazolinderivate zur behandlung von krebserkrankungen
|
EP2340837B1
(de)
*
|
2005-11-11 |
2017-03-15 |
Boehringer Ingelheim International GmbH |
Kombinationsbehandlung gegen krebs mit egfr/her2-hemmern
|
WO2007061127A1
(ja)
*
|
2005-11-22 |
2007-05-31 |
Eisai R & D Management Co., Ltd. |
多発性骨髄腫に対する抗腫瘍剤
|
AU2006321364B2
(en)
*
|
2005-12-01 |
2011-11-10 |
Domantis Limited |
Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
|
EP1968633B2
(de)
|
2006-01-04 |
2017-11-01 |
Institut National de la Santé et de la Recherche Medicale |
Kombinationstherapie mit anti-egfr und anti-her2-antikörpern
|
US8323644B2
(en)
*
|
2006-01-17 |
2012-12-04 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
WO2007128557A1
(en)
|
2006-05-03 |
2007-11-15 |
Bayer Schering Pharma Aktiengesellschaft |
Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
|
WO2007136103A1
(ja)
|
2006-05-18 |
2007-11-29 |
Eisai R & D Management Co., Ltd. |
甲状腺癌に対する抗腫瘍剤
|
EP2044939A1
(de)
*
|
2006-06-29 |
2009-04-08 |
Eisai R&D Management Co., Ltd. |
Therapeutisches mittel gegen leberfibrose
|
ES2427924T3
(es)
|
2006-06-30 |
2013-11-04 |
Merck Sharp & Dohme Corp. |
Biomarcador IGFBP2
|
EP2065372B1
(de)
|
2006-08-28 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Antitumormittel gegen undifferenzierten magenkrebs
|
MX2009007987A
(es)
*
|
2007-01-25 |
2010-03-01 |
Dana Farber Cancer Inst Inc |
Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
|
KR101445892B1
(ko)
|
2007-01-29 |
2014-09-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암 치료용 조성물
|
MX2009008909A
(es)
*
|
2007-03-01 |
2009-08-28 |
Symphogen As |
Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
|
US8877186B2
(en)
*
|
2007-06-06 |
2014-11-04 |
Domantis Limited |
Polypeptides, antibody variable domains and antagonists
|
KR100883430B1
(ko)
*
|
2007-06-13 |
2009-02-12 |
한국생명공학연구원 |
혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
|
WO2008154927A1
(en)
*
|
2007-06-21 |
2008-12-24 |
Genmab A/S |
Novel methods for treating egfr-associated tumors
|
CN108424454B
(zh)
*
|
2007-08-14 |
2022-05-31 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
JP6035009B2
(ja)
|
2007-08-22 |
2016-11-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
|
EP2205249B1
(de)
*
|
2007-09-28 |
2018-11-07 |
Intrexon Corporation |
Therapeutische genschalterkonstrukte und bioreaktoren zur expression biotherapeutischer moleküle und ihre verwendung
|
EP2212432A4
(de)
*
|
2007-10-22 |
2011-10-19 |
Schering Corp |
Vollständig menschliche anti-vegf-antikörper und verwendungsverfahren
|
EP2218712B1
(de)
|
2007-11-09 |
2015-07-01 |
Eisai R&D Management Co., Ltd. |
Kombination einer antiangiogenen substanz und eines platinkomplexes mit antitumorwirkung
|
MX2010008187A
(es)
*
|
2008-01-29 |
2010-08-10 |
Eisai R&D Man Co Ltd |
Uso combinado de inhibidor de angiogenesis y taxano.
|
ES2639857T3
(es)
*
|
2008-02-11 |
2017-10-30 |
Cure Tech Ltd. |
Anticuerpos monoclonales para el tratamiento del tumor
|
BRPI0906099A2
(pt)
*
|
2008-03-06 |
2015-07-21 |
Genentech Inc |
"método de tratamento do câncer em um indivíduo"
|
AR071891A1
(es)
*
|
2008-05-30 |
2010-07-21 |
Imclone Llc |
Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
|
CN102137874B
(zh)
|
2008-08-29 |
2015-02-18 |
西福根有限公司 |
抗表皮生长因子受体的重组抗体组合物
|
GB2467691A
(en)
*
|
2008-09-05 |
2010-08-11 |
Aueon Inc |
Methods for stratifying and annotating cancer drug treatment options
|
BRPI1006141B8
(pt)
|
2009-01-12 |
2021-05-25 |
Cytomx Therapeutics Llc |
composições de anticorpo modificado, métodos para preparar e usar as mesmas
|
WO2010096838A2
(en)
*
|
2009-02-23 |
2010-08-26 |
Cytomx Therapeutics, Llc |
Proproteins and methods of use thereof
|
TW201544123A
(zh)
*
|
2009-03-20 |
2015-12-01 |
Genentech Inc |
抗-her抗體
|
PT2451445T
(pt)
|
2009-07-06 |
2019-07-10 |
Boehringer Ingelheim Int |
Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
|
US20120288495A1
(en)
|
2009-07-22 |
2012-11-15 |
Biothera, Inc. |
Therapeutic compositions and methods
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
WO2011050016A1
(en)
|
2009-10-23 |
2011-04-28 |
Eli Lilly And Company |
Akt inhibitors
|
EP2542692B1
(de)
|
2010-03-04 |
2016-08-24 |
Carpén, Olli |
Verfahren zur auswahl von patienten zur behandlung mit einem egfr-hemmer
|
EP2371369A1
(de)
|
2010-04-01 |
2011-10-05 |
Institut Gustave Roussy (IGR) |
EGFR-Inhibitor und antivirales Mittel zur gleichzeitigen, getrennten oder aufeinanderfolgenden Verwendung bei der Behandlung und/oder Vorbeugung und/oder Abschwächung von Krebs
|
WO2011156617A2
(en)
|
2010-06-09 |
2011-12-15 |
Aveo Pharmaceuticals, Inc. |
Anti-egfr antibodies
|
RU2560683C2
(ru)
|
2010-06-25 |
2015-08-20 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
US9464136B2
(en)
|
2010-08-20 |
2016-10-11 |
Massachusetts Institute Of Technology |
Antibody-based constructs directed against tyrosine kinase receptors
|
EP3572528A1
(de)
|
2010-09-24 |
2019-11-27 |
The Board of Trustees of the Leland Stanford Junior University |
Direkte erfassung, amplifikation und sequenzierung einer ziel-dna unter verwendung immobilisierter primer
|
EP2632489B1
(de)
|
2010-10-27 |
2020-01-15 |
The Research Foundation for The State University of New York |
Zusammensetzungen zur anzielung der löslichen extrazellulären domäne von e-cadherin sowie zugehörige krebstherapieverfahren
|
CN103328505B
(zh)
|
2010-10-29 |
2015-12-02 |
伊缪诺金公司 |
非拮抗性egfr结合分子及其免疫偶联物
|
BR112013010544A2
(pt)
|
2010-10-29 |
2016-08-02 |
Immunogen Inc |
moléculas de ligação ao egfr e imunoconjugados das mesmas
|
EP2640384A1
(de)
|
2010-11-18 |
2013-09-25 |
Synta Pharmaceuticals Corp. |
Vorauswahl von personen für eine therapeutische behandlung mit sauerstoffempfindlichen mitteln auf der basis des hypoxischen status
|
US8628773B2
(en)
|
2011-04-07 |
2014-01-14 |
Amgen Inc. |
Antigen binding proteins
|
CN103402519B
(zh)
|
2011-04-18 |
2015-11-25 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
EA201700111A1
(ru)
|
2011-10-28 |
2018-02-28 |
Тева Фармасьютикал Австралия Пти Лтд |
Полипептидные конструкции и их применение
|
SG11201402343SA
(en)
|
2011-11-21 |
2014-06-27 |
Immunogen Inc |
Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
|
EP2879712B1
(de)
|
2012-07-31 |
2018-04-25 |
Crown Bioscience, Inc. (Taicang) |
Histologische marker zur identifizierung von patienten mit nicht-kleinzelligem bronchialkarzinom zur behandlung mit einem anti-egfr-arzneimittel
|
EA028420B1
(ru)
|
2012-08-07 |
2017-11-30 |
Новартис Аг |
Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа
|
EA029587B1
(ru)
|
2012-10-12 |
2018-04-30 |
Медимьюн Лимитед |
Пирролбензодиазепины и их конъюгаты
|
CN104755463A
(zh)
|
2012-12-21 |
2015-07-01 |
卫材R&D管理有限公司 |
非晶态形式的喹啉衍生物及其生产方法
|
KR102228358B1
(ko)
|
2012-12-21 |
2021-03-16 |
쉬케후세트 솔란데트 에이치에프 |
신경 장애 및 통증의 egfr 표적 치료
|
CN105263319A
(zh)
|
2013-02-13 |
2016-01-20 |
法国化学与生物科技实验室 |
具有经修饰的糖基化的蛋白及其生产方法
|
AR094780A1
(es)
|
2013-02-13 |
2015-08-26 |
Laboratoire Français Du Fractionnement Et Des Biotechnologies |
ANTICUERPOS ANTI-TNF-a ALTAMENTE GALACTOSILADOS Y SUS USOS
|
EP2968585B1
(de)
|
2013-03-13 |
2018-07-18 |
Medimmune Limited |
Pyrrolobenzodiazepine und konjugate davon
|
PL2992013T3
(pl)
|
2013-04-29 |
2020-09-07 |
Teva Pharmaceuticals Australia Pty Ltd |
Przeciwciała anty-cd38 i fuzje z atenuowanym interferonem alfa-2b
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
RU2646098C2
(ru)
*
|
2013-04-30 |
2018-03-01 |
Интас Фармасьютикалс Лтд |
Новый способ клонирования, экспрессии и очистки для получения ранибизумаба
|
US10517861B2
(en)
|
2013-05-14 |
2019-12-31 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
CN110559435B
(zh)
|
2013-09-11 |
2023-10-20 |
伊戈尔生物药品股份有限公司 |
包含离子性液体的液体蛋白质制剂
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
JP2017516458A
(ja)
|
2014-03-24 |
2017-06-22 |
ジェネンテック, インコーポレイテッド |
c−met拮抗剤による癌治療及びc−met拮抗剤のHGF発現との相関
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
EP4089076A1
(de)
|
2014-08-28 |
2022-11-16 |
Eisai R&D Management Co., Ltd. |
Hochreines chinolinderivat und verfahren zum herstellen davon
|
US10188746B2
(en)
|
2014-09-10 |
2019-01-29 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
US11471479B2
(en)
|
2014-10-01 |
2022-10-18 |
Eagle Biologics, Inc. |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
US10385380B2
(en)
|
2014-10-02 |
2019-08-20 |
The Regents Of The University Of California |
Personalized protease assay to measure protease activity in neoplasms
|
WO2016066260A1
(en)
|
2014-10-28 |
2016-05-06 |
Merck Patent Gmbh |
Methods for non-covalent fc-domain-containing protein display on the surface of cells and methods of screening thereof
|
US10544199B2
(en)
|
2014-10-29 |
2020-01-28 |
Teva Pharmaceuticals Australia Pty Ltd |
Interferon alpha 2B variants
|
CA3204990A1
(en)
|
2014-12-05 |
2016-06-09 |
Xyphos Biosciences Inc. |
Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
|
CA2976325C
(en)
|
2015-02-25 |
2023-07-04 |
Eisai R&D Management Co., Ltd. |
Method for suppressing bitterness of quinoline derivative
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
KR20180018695A
(ko)
|
2015-06-16 |
2018-02-21 |
가부시키가이샤 프리즘 파마 |
항암제
|
CN105237638A
(zh)
*
|
2015-10-26 |
2016-01-13 |
无锡傲锐东源生物科技有限公司 |
抗egfr蛋白单克隆抗体杂交瘤细胞及其产生的抗egfr单克隆抗体和应用
|
CN109563166B
(zh)
|
2016-04-28 |
2022-12-20 |
拜奥穆尼克斯制药 |
靶向egfr和her2的双特异性抗体
|
UA125436C2
(uk)
|
2016-06-03 |
2022-03-09 |
Еррей Біофарма, Інк. |
Фармацевтичні комбінації
|
JP2019523016A
(ja)
|
2016-06-24 |
2019-08-22 |
サイフォス、バイオサイエンシズ、インコーポレイテッドXyphos Biosciences Inc. |
抗体の挿入可能な可変フラグメントおよびnkg2dリガンドの改変型a1−a2ドメイン
|
JP2019534882A
(ja)
|
2016-10-11 |
2019-12-05 |
メドイミューン・リミテッドMedImmune Limited |
免疫介在性療法薬を有する抗体−薬物コンジュゲート
|
CN106800599B
(zh)
*
|
2016-12-05 |
2021-03-23 |
中国人民解放军第二军医大学 |
抗人EGFR和Notch多特异性抗体、其制备方法及用途
|
MX2019006504A
(es)
|
2017-02-08 |
2019-08-14 |
Eisai R&D Man Co Ltd |
Composicion farmaceutica de tratamiento de tumores.
|
SG11202003754YA
(en)
|
2017-05-16 |
2020-05-28 |
Bhamis Research Laboratory Pvt Ltd |
High concentration protein formulations with reduced viscosity
|
US11123330B2
(en)
|
2017-09-28 |
2021-09-21 |
The Governing Council Of The University Of Toronto |
Methods and compositions for inhibiting mutant EGFR signaling
|
BR112020023846A2
(pt)
|
2018-05-23 |
2021-04-13 |
Adc Therapeutics Sa |
Adjuvante molecular
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
KR20210116437A
(ko)
|
2018-11-20 |
2021-09-27 |
코넬 유니버시티 |
방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
|
EP3947440A1
(de)
|
2019-03-29 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Verfahren zur erzeugung von avid-bindenden multispezifischen antikörpern
|
WO2020225552A1
(en)
|
2019-05-06 |
2020-11-12 |
Medimmune Limited |
Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
EP4317188A1
(de)
|
2021-03-31 |
2024-02-07 |
Nihon Medi-Physics Co., Ltd. |
Radioaktiver komplex eines anti-egfr-antikörpers und radiopharmazeutikum
|
WO2022262879A1
(es)
|
2021-06-14 |
2022-12-22 |
Centro De Inmunología Molecular |
Uso de anticuerpos monoclonales contra el receptor del factor de crecimiento epidérmico en el tratamiento de pacientes con insuficiencia respiratoria aguda hipoxémica
|
WO2023288267A1
(en)
|
2021-07-14 |
2023-01-19 |
2Seventy Bio, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
WO2023166098A1
(en)
|
2022-03-02 |
2023-09-07 |
Biomunex Pharmaceuticals |
Bispecific antibodies binding to her-3 and to either her-2 or egfr
|
WO2023196997A2
(en)
|
2022-04-08 |
2023-10-12 |
2Seventy Bio, Inc. |
Multipartite receptor and signaling complexes
|